SUPERNEWS - NASDAQ:AMGN (Amgen Inc.) Stock Price, News, Quote, History

SUPERNEWS

Equities

Top Stories

Amgen Surges 12% on MariTide Hopes, Eyes Obesity Market

Amgen Up 12% on MariTide, Targets $80B Market by 2030

Amgen's shares surge 12% on CEO's optimism for experimental obesity drug MariTide, signaling a strong entry into the competitive weightloss market.

5/2, 17:49 EDT

Intraday: Fed Rate Cut Hopes Spark 1.1% S&P Surge, Tech Leads

Investor optimism on potential Federal Reserve rate cuts by September fueled a 1.1% rise in the S&P 500, with Amgen (AMGN) and Apple (AAPL) leading gains due to positive drug study feedback and strong China sales. Tandem Diabetes (TNDM) and WideOpenWest (WOW) stood out with shares soaring 26% and 30%, respectively, highlighting market opportunities amidst mixed sector performances.

5/3, 10:51 EDT

Pre-Market: Tech and Healthcare Stocks Fuel Market Optimism, S&P Up 0.4%

Tech and healthcare stocks, led by Apple (AAPL) with a 6.2% increase and Amgen (AMGN) surging 14%, drive premarket optimism as S&P 500 futures rise by 0.4%. - Despite overall market buoyancy, companies like BigBear.ai (BBAI) and Cloudflare (NET) see significant drops of 14% and 13%, highlighting the market's volatility ahead of the jobs report.

5/3, 07:52 EDT

Novo Down 5.3%, Amgen Up as Obesity Drug Race Heats Up

Novo Nordisk's stock falls 5.3% amid competition fears as Amgen's obesity drug MariTide shows promise, shaking up the $80 billion market.

5/3, 05:44 EDT

Amgen Surges 12% on MariTide Hopes, Eyes Obesity Market

5/6, 09:07 EDT

Amgen Up 12% on MariTide, Targets $80B Market by 2030

5/2, 17:49 EDT

Intraday: Fed Rate Cut Hopes Spark 1.1% S&P Surge, Tech Leads

5/3, 10:51 EDT

AMGN News

Intraday: Biotech Shocks: MacroGenics Plunges, Novavax Soars

5/10, 13:51 EDT

Pre-Market: Novavax Soars 54% on Sanofi Deal, MacroGenics Tumbles 67%

5/10, 06:28 EDT

SiTime Soars, Akamai and EPAM Face Headwinds

5/9, 19:57 EDT

InMed Advances Alzheimer's Drug INM-901, Adds Expert to Team

5/6, 09:35 EDT

Amgen Surges 12% on MariTide Hopes, Eyes Obesity Market

5/6, 09:07 EDT

Jobs Report Fuels Rally: S&P 500 Up 1.2%, Apple Jumps 7%, Bitcoin at $61K

5/3, 14:13 EDT

Intraday: Tech and Pharma Lead Market Surge on Fed Cut Hopes

5/3, 14:07 EDT

Intraday: Fed Rate Cut Hopes Spark 1.1% S&P Surge, Tech Leads

5/3, 10:51 EDT

Pre-Market: Futures Up on Jobs Optimism, Amgen Soars 14%

5/3, 09:05 EDT

Pre-Market: Tech and Healthcare Stocks Fuel Market Optimism, S&P Up 0.4%

5/3, 07:52 EDT

Novo Down 5.3%, Amgen Up as Obesity Drug Race Heats Up

5/3, 05:44 EDT

Amgen Up 12% on MariTide, Targets $80B Market by 2030

5/2, 17:49 EDT

After-Market: Tech Stocks Swing: Amgen, Apple Soar; Cloudflare, Expedia Dip

5/2, 17:23 EDT

Seritage Sells Albany Mall Section for $28M, Heidenberg Buys

5/1, 14:25 EDT

AI Disappointments Dampen Tech Optimism, Fed Watch Looms

5/1, 08:13 EDT

Wage Pressures Sink Stocks, Bonds Amid Inflation Fears

4/30, 19:53 EDT

Wells Fargo Upgrades Neurocrine, Targets $170 Amid Bullish View

4/24, 11:29 EDT

Amgen Pullback Signals Buy; Ultragenyx Targets 82% Upside

4/22, 12:43 EDT

Ultragenyx Rated 'Outperform' by RBC, 82% Upside Seen

4/22, 11:53 EDT

Moderna vs. Pfizer in London Over mRNA Patents

4/22, 00:11 EDT

Dow Struggles to Break 40,000 Barrier Amid Psychological Resistance

4/1, 16:34 EDT

Analysts Warn: Earnings Optimism May Hit Reality Wall

3/26, 09:47 EDT

Stocks with Attractive Yields and Stable Dividends Identified Through Barron's Screen

3/7, 15:27 EST

Safer Dividend Stocks Identified for Balanced Income and Risk Mitigation

3/7, 15:24 EST

Amazon's Dow Entry Signals Shift to Digital Economy Era

2/20, 17:48 EST

US Stocks Climb Despite Mixed Earnings Landscape

2/7, 13:58 EST

US Stocks Rally Ahead of Fed's Economic Insights

2/7, 08:59 EST

Wall Street Analysts Issue Diverse Recommendations Amid Market Uncertainties

2/7, 08:38 EST

Amgen Surges on Q4 Beat, Obesity Drug Promise

2/6, 17:01 EST

Health-Care Stocks Lead Market Surge, Ford Earnings Awaited

2/5, 19:49 EST

Wall Street Views

Chicago Fed President

Austan Goolsbee, 5/3/24

Neutral on

AAPL

AMGN

“It boosts confidence that the economy is not overheating and inflation is not reaccelerating.”

Barclays Plc

Emily Field, 5/3/24

Neutral on

AMGN

LLY

NVO

“As of today, we see no cause for concern regarding the competitive dynamics versus the market leaders... We really will need to see the data.”

Bloomberg Intelligence

Michael Shah, 5/2/24

Bullish on

AAPL

AMGN

EXPE

“Demand for anti-obesity drugs like Zepbound and Wegovy is so insatiable that Bloomberg Intelligence’s estimate for $80 billion in annual sales by 2030 is now looking conservative.”

Trivariate Research

Adam Parker, 3/26/24

Cautiously Optimistic on

ABBV

ABT

AMGN

“Full year 2024 guidance has not been reduced. This in effect creates an ‘implied’ 2H of 2024 guidance that is perhaps excessively optimistic.”

“Against this backdrop, Parker recommended investors be overweight in health care and energy sectors, where he believes companies are more likely to meet estimates, and to be equal-weight in technology — where he prefers 'accelerating but low-growth software and AI-semiconductors.'”

Senior Index Analyst at S&P Dow Jones Indices

Howard Silverblatt, 2/1/24

AMGN

CRM

GOOGL

“Selecting a company for any index is part art and part science. With the Dow, it becomes a lot more art.”